Safety evaluation of the preemptive immune-cell therapy against cancer.

A clinical study on the safety of the preventive gdT cell therapy against cancer.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTc030190260

Enrollment

650

Registered

2020-03-16

Start date

2015-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

blood collection for cell culture and tests.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Have risk factors for cancer and desire for receiving the preemptive immune-cell therapy. (2)Be > 18 of age when obtaining the informed consent. (3)Provide written informed consent. (4)Be determined to be appropriate by the doctor in charge.

Exclusion criteria

Exclusion criteria: (1)Be diagnosed with cancer. (2)Desire to receive the immune-cell therapy for the treatment of any allergic disease. (3)Be HIV or HTLV-1 positive. (4)Be an allotransplant recipient. (5)Have a history or sign of interstitial pneumonia. (6)Have an active autoimmune disease. (7)Be a female who is pregnant, nursing, or of childbearing potential. (8)A subject 70 years of age and above must be carefully considered for the risk of an autoimmune disease to enroll in this study. (9)Be determined to be inappropriate by the doctor in charge.

Design outcomes

Primary

Measure	Time frame
Safety, Immunological response	—

Secondary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactTakashi Kamigaki

Koshikai, Non-profit Medical Corporation

citeg@j-immunother.com+81-3-5244-5751

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026